Ser177
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser177  -  PARP1 (mouse)

Site Information
LGFRPEYsASQLKGF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 18013484

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
HUVEC (endothelial) ( 1 )

Upstream Regulation
Putative in vivo kinases:
AMPKA2 (human) ( 1 )
Treatments:
angiotensin_2 ( 1 ) , H2O2 ( 1 ) , high_glucose ( 1 ) , metformin ( 1 ) , telmisartan ( 1 )

References 

1

Shang F, et al. (2016) Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade. PLoS One 11, e0151845
26986624   Curated Info